Weekly US Influenza Surveillance Report: Key Updates for Week 44, ending November 7, 2026

Summary

All data are preliminary and may change as more reports are received.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page. Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

U.S. Virologic Surveillance

Nationally, and in HHS regions 1 – 7, and 10, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories increased (change of at least 0.5 percentage points) compared to the previous week. In Region 8, the percentage remained stable compared to the previous week. The percentage of positive specimens decreased in Region 9 compared to the previous week, which could be due to incomplete reporting. A(H1N1)pdm09 viruses were the most frequently reported influenza viruses by public health laboratories this week and this season. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent receipt of live attenuated influenza vaccine (LAIV) or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.

Clinical Laboratories

The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza virus) are used to monitor whether influenza activity is increasing or decreasing.

Public Health Laboratories

The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating influenza viruses that belong to each influenza subtype.

_{^†When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but person-to-person transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.}

_{*These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested are not the same as human cases of A(H5) virus infection). If a specimen is only tested at CDC, it is not reflected in these data. The data could include more than one specimen tested per person. For more information on the number of people infected with A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"}

_{This graph reflects the number of specimens determined to be positive for influenza viruses at the public health laboratory (specimens tested are not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.}

Novel Influenza A Virus Infections

No new confirmed human infections with a novel influenza virus were reported to CDC as of November 7, 2026.

Novel influenza A virus infections include human infections with influenza A viruses that are different from currently circulating human seasonal influenza A(H1) and A(H3) viruses or avian influenza A viruses that have sporadically infected people.

The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/position_statements_files_2023/24-ID-09_Novel_Influenza_A.pdf.

An up-to-date summary of human cases in the United States since 2024, by state and exposure source, is available at www.cdc.gov/bird-flu/situation-summary/index.html.

Information about avian influenza is available at https://www.cdc.gov/bird-flu/.

Interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html.

The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

Influenza Virus Characterization

CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are relative to the reference viruses representing the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the polymerase acidic protein (PA) endonuclease inhibitor baloxavir. The HA clade and subclades were assigned using Nextclade (https://clades.nextstrain.org).

CDC has genetically characterized 764 influenza viruses collected since May 24, 2026.

Genetic Characterization of Hemagglutinin Genes from Influenza Viruses Collected since May 24, 2026

CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) assay (H1N1pdm09, H3N2, and B/Victoria viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2026-2027 Northern Hemisphere recommended cell-, recombinant- and nucleic acid-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than 8-fold. Viruses selected for antigenic characterization are a subset of the recent genetically characterized viruses and are chosen based on the genetic changes in their surface proteins and may not be proportional to the number of such viruses circulating in the United States.

Influenza A Viruses

• A(H1N1)pdm09: 147 A(H1N1)pdm09 viruses were antigenically characterized by HI, and 140 (95.2%) were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Missouri/11/2025-like reference viruses representing the A(H1N1)pdm09 component for the cell-, recombinant- and nucleic acid-based influenza vaccines.
• A(H3N2): 35 A(H3N2) viruses were antigenically characterized by HI or HINT, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer in HI or reacting at titers that were less than 8-fold of the homologous virus in HINT) by ferret antisera to cell-grown A/Darwin/1415/2025-like reference viruses representing the A(H3N2) component for the cell-, recombinant- and nucleic acid-based influenza vaccines.

Influenza B Viruses

• B/Victoria: 33 influenza B/Victoria-lineage viruses were antigenically characterized by HI, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Pennsylvania/14/2025-like reference viruses representing the B/Victoria component for the cell-, recombinant- and nucleic acid-based influenza vaccines.

Assessment of Virus Susceptibility to Antiviral Medications

CDC assesses susceptibility of influenza viruses to the antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir using next generation sequence analysis supplemented by laboratory assays. Information about antiviral susceptibility test methods can be found at U.S. Influenza Surveillance: Purpose and Methods | CDC.

Viruses collected in the U.S. since May 24, 2026, were tested for antiviral susceptibility as follows:

Eight A(H1N1)pdm09 viruses had amino acid substitutions NA-I223V and NA-S247N and showed reduced inhibition by oseltamivir.

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A(H1N1)pdm09 and influenza A(H3N2) viruses (the adamantanes are not effective against influenza B viruses). Therefore, use of these antivirals for treatment and prevention of influenza A virus infection is not recommended and data from adamantane resistance testing are not presented.

Outpatient and Emergency Department Illness Surveillance

ILINet

The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient and emergency department visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and can therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms. It is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete picture.

Nationally, during Week 44, 3.2% of patient visits reported through ILINet were due to ILI. This week’s national percentage increased (change of > 0.1 percentage points) compared to Week 43 and is above the national baseline of 2.9%. ILI activity decreased in Region 2, which is most likely due to incomplete data for that region. ILI activity remained stable (change of ≤ 0.1 percentage points) but is trending upwards in regions 5 and 7, and increased in all other HHS regions (1, 3, 4, 6, 8, 9, 10) compared to Week 43. Region 1 is at its baseline, regions 4, 6, 9, and 10 are above their respective baselines, and all other regions (2, 3, 5, 7, and 8) are below their baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

_{*Some calendar years do not include an epidemiologic Week 53. In those years, the Week 53 value shown is the average between Week 52 and Week 1.}

_{**Effective October 3, 2021 (Week 40), the respiratory illness definition (fever plus cough or sore throat) no longer includes "without a known cause other than influenza."}

The percentage of visits for respiratory illness increased (change of > 0.1 percentage points) in the 0-4 years, 5-24 years, 25-49 years, and 50-64 years age groups and remained stable but is trending upwards in the 65 years and older age groups this week compared to the previous week.

ILI Activity Map

Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).

National Syndromic Surveillance System (NSSP)

The national percentage of emergency department (ED) visits with a discharge diagnosis (DD) of influenza reported in NSSP was 2.2% during Week 44 and increased (change of > 0.1 percentage point) compared to the previous week. Nationally, the percentage of ED visits with a DD of influenza increased among three age groups (0-4 years, 5-17 years and 18-64 years) and remained stable (change of ≤ 0.1 percentage point) but is trending upward among those 65 years and older this week compared to the previous week. The percentage of ED visits with a DD of influenza remained stable in Region 7 and increased in all other HHS regions this week compared to the previous week.

Hospitalization Surveillance

FluSurv-NET

The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 10% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.

A total of 3,262 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 4, 2026, and November 7, 2026. The weekly hospitalization rate observed during Week 44 was 1.8 per 100,000 population. After accounting for reporting delays, the estimated rate during Week 44 likely ranges from 2.2 to 2.9. Estimated weekly rates continue to increase. The cumulative hospitalization rate observed in Week 44 was 8.7 per 100,000 population.

Among all hospitalizations, 3,195 (97.9%) were associated with influenza A virus, 59 (1.8%) with influenza B virus, 1 (<0.1%) with influenza A virus and influenza B virus co-infection, and 7 (0.2%) with influenza virus for which the type was not determined. Among those with influenza A subtype information, 6 (1.0%) were A(H3N2), and 591 (99.0%) were A(H1N1)pdm09.

When examining rates by age, the highest rate of hospitalization per 100,000 population was among adults aged 65 and older (28.0), followed by adults aged 50-64 years (9.4), children aged 0-4 years (8.3), children aged 5-17 years (3.0), and adults aged 18-49 years (2.7).

When examining age-adjusted rates by race and ethnicity, the highest rate of hospitalization per 100,000 population was among non-Hispanic Black persons (14.4), followed by Asian and/or Pacific Islander persons (10.3), American Indian or Alaska Native persons (8.6), Hispanic persons (8.4), and non-Hispanic White persons (6.8).

National Healthcare Safety Network (NHSN) Hospital Respiratory Data

Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 44, 9,584 laboratory-confirmed, influenza-associated hospitalizations were reported. This week's influenza-associated hospital admission rate (2.8 per 100,000 population) increased (difference of ≥ 0.25) compared to Week 43.

Laboratory-confirmed influenza-associated hospital admission rates per 100,000 population increased in regions 1, 2, 4, 6, and 10, remained stable in regions 3, 5, 8, and 9, and decreased in Region 7, which could be due to incomplete reporting this week compared to the previous week. Regional admission rates during Week 44 ranged from 0.7 (Region 7) to 4.0 (Region 2).

When examining rates by age for Week 44, the 0-4 years and 65 years and older age groups increased (difference of ≥ 0.25) and the 5-17 years, 18-49 years, and 50-64 years age groups remained stable (difference of < 0.25) compared to the previous week. The highest hospital admission rate per 100,000 population was among those 65 years and older (8.6), followed by the 0-4 years age group (3.2), and the 50-64 years age group (2.7).

Mortality Surveillance

National Center for Health Statistics (NCHS)

Based on NCHS mortality surveillance data available on November 12, 2026, 0.4% of the deaths that occurred during the week ending November 7, 2026 (Week 44) were due to influenza. This percentage remained stable (< 0.1 percentage point change) compared to Week 43 but has been trending upward over the past eight weeks. The data presented are preliminary and may change as more data are received and processed.

Influenza-Associated Pediatric Mortality

Three influenza-associated pediatric deaths were reported to CDC during Week 44.

Two deaths occurred during the 2026-2027 season, bringing the total pediatric deaths for this season to five. The deaths occurred during Week 41 (the week ending October 17, 2026) and Week 44 (the week ending November 7, 2026). Both deaths were associated with influenza A viruses. One of the influenza A viruses had subtyping performed and it was an A(H1N1) virus.

One death occurring during the 2025-2026 season was also reported, which brings the total number of pediatric deaths for last season to 203. This death was associated with an influenza A(H3) virus and occurred during Week 6 of 2026 (the week ending February 14, 2026).

For surveillance purposes, an influenza-associated pediatric death is defined as a death in a person less than 18 years of age, resulting from a clinically compatible illness that was confirmed to be influenza by an appropriate laboratory diagnostic test. There should be no period of complete recovery between the illness and death.

The data presented are preliminary and may increase as additional cases are identified and reported to CDC.

Additional National and International Influenza Surveillance Information